Evidence map›Paper›PMID 29344245›Full record

ArticleOncology letters2017

Overexpression of NEDD9 in renal cell carcinoma is associated with tumor migration and invasion.

Jue Wang, Si Wang, Yun Luan, Wenhua Zhang, Chao Sun, Guanghui Cheng, Kailin Li, Qian Xin, Zhaomin Lin, Tonggang Qi and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Jue WangCentral Laboratory, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China.
Si WangDepartment of Neurology, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China.
Yun LuanCentral Laboratory, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China.
Wenhua ZhangDepartment of Urology, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China.
Chao SunCentral Laboratory, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China.
Guanghui ChengCentral Laboratory, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China.
Kailin LiCentral Laboratory, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China.
Qian XinCentral Laboratory, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China.
Zhaomin LinCentral Laboratory, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China.
Tonggang QiCentral Laboratory, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China.
Feng KongCentral Laboratory, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China.
Second Hospital of Shandong University · CNQilu Hospital of Shandong University · CNShandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Scaffold protein neural precursor cell expressed, developmentally downregulated 9 (NEDD9) is a member of the Crk-associated substrate protein family and is known to be a biomarker in multiple cancer types. It serves a critical function in regulating cell proliferation, migration, invasion and survival. The objective of this study was to evaluate the potential effects of NEDD9 in renal cell carcinoma (RCC). The expression of NEDD9 was analyzed by immunohistochemistry, western blotting and reverse transcription-quantitative polymerase chain reaction. NEDD9 protein and mRNA levels were significantly upregulated in RCC tissues compared with normal tissues (P<0.001). Furthermore, the NEDD9 immunostaining level was significantly associated with primary tumor stage and tumor, node, metastasis stage (P<0.05). High NEDD9 expression resulted in significantly lower survival rates for patients compared with normal NEDD9 expression (P<0.01). In addition, wound healing and transwell assays indicated that NEDD9 depletion by small interfering RNA significantly attenuated the migration and invasion of RCC cells (P<0.001). The present data suggested that NEDD9 may be a novel target for prevention and treatment of RCC metastasis and recurrence.

Indexed as

clinicopathological factorsinvasionmigrationneural precursor cell expressed developmentally downregulated 9renal cell carcinoma

Identifiers

PMID29344245
PMCPMC5755160
OpenAlexW2766536696

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.